提高囊性纤维化患者的预期寿命：进展与挑战。
Increasing life expectancy in cystic fibrosis: Advances and challenges.
机构信息
Case Western Reserve University School of Medicine, Cleveland, Ohio, USA.
Rainbow Babies and Children's Hospital, Cleveland, Ohio, USA.
出版信息
Pediatr Pulmonol. 2022 Feb;57 Suppl 1(Suppl 1):S5-S12. doi: 10.1002/ppul.25733. Epub 2021 Nov 11.
Abstract
Since the first description of cystic fibrosis in 1938, there have been significant advances in both quality of life and longevity for people living with this disease. In this article we describe the milestones of the last 80 years and what we perceive to be the remaining barriers to normalcy for this population.
摘要
自 1938 年首次描述囊性纤维化以来，患有这种疾病的人的生活质量和寿命都有了显著提高。本文描述了过去 80 年的里程碑事件，以及我们认为该人群仍面临的正常化障碍。
相似文献
1
Increasing life expectancy in cystic fibrosis: Advances and challenges.
Pediatr Pulmonol. 2022 Feb;57 Suppl 1(Suppl 1):S5-S12. doi: 10.1002/ppul.25733. Epub 2021 Nov 11.
2
Optimising the care and quality of life of people with cystic fibrosis: the influence of cystic fibrosis transmembrane conductance regulator modulators.
Br J Hosp Med (Lond). 2021 Nov 2;82(11):1-6. doi: 10.12968/hmed.2021.0530. Epub 2021 Nov 22.
3
Ivacaftor: the first therapy acting on the primary cause of cystic fibrosis.
Drugs Today (Barc). 2013 Apr;49(4):253-60. doi: 10.1358/dot.2013.49.4.1940984.
4
A new era for people with cystic fibrosis.
Eur J Pediatr. 2021 Sep;180(9):2731-2739. doi: 10.1007/s00431-021-04168-y. Epub 2021 Jul 2.
5
Potentiators (specific therapies for class III and IV mutations) for cystic fibrosis.
Cochrane Database Syst Rev. 2015 Mar 26(3):CD009841. doi: 10.1002/14651858.CD009841.pub2.
6
New Therapeutic Approaches to Modulate and Correct Cystic Fibrosis Transmembrane Conductance Regulator.
Pediatr Clin North Am. 2016 Aug;63(4):751-64. doi: 10.1016/j.pcl.2016.04.006.
7
The Extrapulmonary Effects of Cystic Fibrosis Transmembrane Conductance Regulator Modulators in Cystic Fibrosis.
Ann Am Thorac Soc. 2020 Feb;17(2):147-154. doi: 10.1513/AnnalsATS.201909-671CME.
8
[Therapeutic update in cystic fibrosis].
Rev Med Interne. 2014 Jun;35(6):388-92. doi: 10.1016/j.revmed.2013.11.003. Epub 2013 Dec 3.
9
Cystic fibrosis transmembrane conductance receptor modulator therapy in cystic fibrosis, an update.
Curr Opin Pediatr. 2020 Jun;32(3):384-388. doi: 10.1097/MOP.0000000000000892.
10
Cystic fibrosis transmembrane conductance regulator modulators: Present and future in cystic fibrosis treatment. A review.
Arch Argent Pediatr. 2019 Apr 1;117(2):e131-e136. doi: 10.5546/aap.2019.eng.e131.
引用本文的文献
1
Image quality in ultra-low-dose chest CT versus chest x-rays guiding paediatric cystic fibrosis care.
Eur Radiol. 2025 Jul 25. doi: 10.1007/s00330-025-11835-3.
2
Impact of CFTR Modulators on Longitudinal Cystic Fibrosis Survival and Mortality: Review and Secondary Analysis.
Pulm Ther. 2025 Jul 11. doi: 10.1007/s41030-025-00303-4.
3
Cholinergic Signaling Modulates Intestinal Pathophysiology in a Model of Cystic Fibrosis.
bioRxiv. 2025 Jul 5:2025.07.02.662792. doi: 10.1101/2025.07.02.662792.
4
The impact of cystic fibrosis transmembrane conductance regulator (CFTR) modulators on the pulmonary microbiota.
Microbiology (Reading). 2025 Apr;171(4). doi: 10.1099/mic.0.001553.
5
Hypogonadism in a Man With Cystic Fibrosis and an Unusually Low Serum Testosterone: A Cautionary Tale.
AACE Clin Case Rep. 2024 Oct 4;11(1):32-35. doi: 10.1016/j.aace.2024.09.008. eCollection 2025 Jan-Feb.
6
Anesthetic Management and Considerations for Cesarean Delivery in a Patient With Cystic Fibrosis.
Case Rep Anesthesiol. 2025 Jan 21;2025:6388254. doi: 10.1155/cria/6388254. eCollection 2025.
7
A Global Perspective on Transition Models for Pediatric to Adult Cystic Fibrosis Care: What Has Been Made So Far?
J Clin Med. 2024 Dec 6;13(23):7428. doi: 10.3390/jcm13237428.
8
Immunodeficiencies and CFTR dysfunction: results from a systematic screening in a cohort of adults with cystic fibrosis and CFTR-related disorders.
Ther Adv Respir Dis. 2024 Jan-Dec;18:17534666241253945. doi: 10.1177/17534666241253945.
9
Genomic and phenotypic characterization of isolates from two Mexican cystic fibrosis attention centers.
Microbiol Spectr. 2024 Oct 23;12(12):e0110024. doi: 10.1128/spectrum.01100-24.
10
Current landscape of cystic fibrosis gene therapy.
Front Pharmacol. 2024 Oct 8;15:1476331. doi: 10.3389/fphar.2024.1476331. eCollection 2024.
本文引用的文献
1
Outcomes of infants born during the first 9 years of CF newborn screening in the United States: A retrospective Cystic Fibrosis Foundation Patient Registry cohort study.
Pediatr Pulmonol. 2021 Dec;56(12):3758-3767. doi: 10.1002/ppul.25658. Epub 2021 Sep 13.
2
CRISPR-Cas9 In Vivo Gene Editing for Transthyretin Amyloidosis.
N Engl J Med. 2021 Aug 5;385(6):493-502. doi: 10.1056/NEJMoa2107454. Epub 2021 Jun 26.
3
The Future of Highly Effective Modulator Therapy in Cystic Fibrosis.
Am J Respir Crit Care Med. 2021 Jun 15;203(12):1453-1455. doi: 10.1164/rccm.202104-0850ED.
4
Normal pancreatic function and false-negative CF newborn screen in a child born to a mother taking CFTR modulator therapy during pregnancy.
J Cyst Fibros. 2021 Sep;20(5):835-836. doi: 10.1016/j.jcf.2021.03.018. Epub 2021 Apr 9.
5
Racially equitable diagnosis of cystic fibrosis using next-generation DNA sequencing: a case report.
BMC Pediatr. 2021 Mar 31;21(1):154. doi: 10.1186/s12887-021-02609-z.
6
Long-term safety and efficacy of tezacaftor-ivacaftor in individuals with cystic fibrosis aged 12 years or older who are homozygous or heterozygous for Phe508del CFTR (EXTEND): an open-label extension study.
Lancet Respir Med. 2021 Jul;9(7):733-746. doi: 10.1016/S2213-2600(20)30510-5. Epub 2021 Feb 10.
7
Cystic fibrosis patients of minority race and ethnicity less likely eligible for CFTR modulators based on CFTR genotype.
Pediatr Pulmonol. 2021 Jun;56(6):1496-1503. doi: 10.1002/ppul.25285. Epub 2021 Feb 1.
8
Real-World Safety of CFTR Modulators in the Treatment of Cystic Fibrosis: A Systematic Review.
J Clin Med. 2020 Dec 23;10(1):23. doi: 10.3390/jcm10010023.
9
Long term clinical effectiveness of ivacaftor in people with the G551D CFTR mutation.
J Cyst Fibros. 2021 Mar;20(2):213-219. doi: 10.1016/j.jcf.2020.11.008. Epub 2020 Nov 25.
10
Psychological Impact of NBS for CF.
Int J Neonatal Screen. 2020 Mar 30;6(2):27. doi: 10.3390/ijns6020027. eCollection 2020 Jun.
Zotero 插件